Literature DB >> 16287208

Mechanisms of action of ribavirin against distinct viruses.

Jason D Graci1, Craig E Cameron.   

Abstract

The nucleoside analogue ribavirin has antiviral activity against many distinct viruses both in vitro and in vivo. Five distinct mechanisms have been proposed to explain the antiviral properties of ribavirin. These include both indirect mechanisms (inosine monophosphate dehydrogenase inhibition, immunomodulatory effects) and direct mechanisms (interference with RNA capping, polymerase inhibition, lethal mutagenesis). Recent concerns about bioterrorism have renewed interest in exploring the antiviral activity of ribavirin against unique viruses. In this paper, we review the proposed mechanisms of action with emphasis on recent discoveries, as well as the implications of ribavirin resistance. Evidence exists to support each of the five proposed mechanisms of action, and distinct virus/host combinations may preferentially favour one or more of these mechanisms during antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16287208      PMCID: PMC7169142          DOI: 10.1002/rmv.483

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  81 in total

1.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

2.  Studies on the mechanism of the antiviral activity of ribavirin against reovirus.

Authors:  J T Rankin; S B Eppes; J B Antczak; W K Joklik
Journal:  Virology       Date:  1989-01       Impact factor: 3.616

3.  A new class of synthetic nucleoside analogues with broad-spectrum antiviral properties.

Authors:  P Prusiner; M Sundaralingam
Journal:  Nat New Biol       Date:  1973-07-25

4.  The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.

Authors:  Pieter Leyssen; Jan Balzarini; Erik De Clercq; Johan Neyts
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA.

Authors:  Julie K Pfeiffer; Karla Kirkegaard
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro.

Authors:  D F Smee; M Bray; J W Huggins
Journal:  Antivir Chem Chemother       Date:  2001-11

7.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

Review 8.  Potential importance of error catastrophe to the development of antiviral strategies for hantaviruses.

Authors:  Colleen B Jonsson; Brook G Milligan; Jeffrey B Arterburn
Journal:  Virus Res       Date:  2005-02       Impact factor: 3.303

9.  Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription.

Authors:  P Toltzis; K O'Connell; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  165 in total

1.  Mechanism of RNA synthesis initiation by the vesicular stomatitis virus polymerase.

Authors:  Benjamin Morin; Amal A Rahmeh; Sean P J Whelan
Journal:  EMBO J       Date:  2012-01-13       Impact factor: 11.598

2.  Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.

Authors:  Toru Yamaguchi-Sasaki; Seiken Tokura; Yuya Ogata; Takanori Kawaguchi; Yutaka Sugaya; Ryo Takahashi; Kanako Iwakiri; Tomoko Abe-Kumasaka; Ippei Yoshida; Kaho Arikawa; Hiroyuki Sugiyama; Kosuke Kanuma
Journal:  ACS Med Chem Lett       Date:  2020-04-10       Impact factor: 4.345

3.  Theory of lethal mutagenesis for viruses.

Authors:  J J Bull; R Sanjuán; C O Wilke
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  Antiviral activities of flavonoids isolated from the bark of Rhus verniciflua stokes against fish pathogenic viruses In Vitro.

Authors:  So Young Kang; Ji-Young Kang; Myung-Joo Oh
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

Review 5.  IMP dehydrogenase: structure, mechanism, and inhibition.

Authors:  Lizbeth Hedstrom
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

6.  Lethal mutagenesis of bacteria.

Authors:  James J Bull; Claus O Wilke
Journal:  Genetics       Date:  2008-09-09       Impact factor: 4.562

7.  Model systems for the study of human norovirus Biology.

Authors:  S Vashist; D Bailey; A Putics; I Goodfellow
Journal:  Future Virol       Date:  2009-07       Impact factor: 1.831

8.  Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin.

Authors:  Armando Arias; Jamie J Arnold; Macarena Sierra; Eric D Smidansky; Esteban Domingo; Craig E Cameron
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

Review 9.  Dynamics: the missing link between structure and function of the viral RNA-dependent RNA polymerase?

Authors:  Craig E Cameron; Ibrahim M Moustafa; Jamie J Arnold
Journal:  Curr Opin Struct Biol       Date:  2009-11-10       Impact factor: 6.809

10.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.